[go: up one dir, main page]

MA32617B1 - Traitement de l'hypertension arterielle pulmonaire - Google Patents

Traitement de l'hypertension arterielle pulmonaire

Info

Publication number
MA32617B1
MA32617B1 MA33678A MA33678A MA32617B1 MA 32617 B1 MA32617 B1 MA 32617B1 MA 33678 A MA33678 A MA 33678A MA 33678 A MA33678 A MA 33678A MA 32617 B1 MA32617 B1 MA 32617B1
Authority
MA
Morocco
Prior art keywords
treatment
arterial hypertension
pulmonary arterial
pulmonary
hypertension
Prior art date
Application number
MA33678A
Other languages
Arabic (ar)
English (en)
Inventor
Steve Pascoe
Deborah Quinn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32617(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32617B1 publication Critical patent/MA32617B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation du 4-(4-méthylpipérazin-1-yl-méthyl)-n-[4-méthyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phényl]-benzamide ou de l'un de ses sels pharmaceutiquement acceptables ou d'un pyrimidylaminobenzamide de formule i dans laquelle les radicaux et les symboles sont tels que définis dans ce document, ou de l'un de ses sels pharmaceutiquement acceptables, pour la fabrication d'un médicament destiné au traitement de l'hypertension artérielle pulmonaire (hap), spécialement chez les patients pour lesquels un traitement antérieur de la hap a échoué.
MA33678A 2008-08-13 2011-03-07 Traitement de l'hypertension arterielle pulmonaire MA32617B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US16450109P 2009-03-30 2009-03-30
PCT/US2009/053358 WO2010019540A1 (fr) 2008-08-13 2009-08-11 Traitement de l’hypertension artérielle pulmonaire

Publications (1)

Publication Number Publication Date
MA32617B1 true MA32617B1 (fr) 2011-09-01

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33678A MA32617B1 (fr) 2008-08-13 2011-03-07 Traitement de l'hypertension arterielle pulmonaire

Country Status (16)

Country Link
US (1) US20110190313A1 (fr)
EP (1) EP2315592A1 (fr)
JP (1) JP2011530607A (fr)
KR (1) KR20110053354A (fr)
CN (1) CN102123711A (fr)
AU (1) AU2009282104A1 (fr)
BR (1) BRPI0917491A2 (fr)
CA (1) CA2732789A1 (fr)
CL (1) CL2011000295A1 (fr)
IL (1) IL210922A0 (fr)
MA (1) MA32617B1 (fr)
MX (1) MX2011001668A (fr)
NZ (1) NZ590839A (fr)
RU (1) RU2011109078A (fr)
TW (1) TW201010999A (fr)
WO (1) WO2010019540A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
CN109568319A (zh) 2013-01-10 2019-04-05 普尔莫凯恩股份有限公司 非选择性激酶抑制剂
WO2015017728A1 (fr) 2013-07-31 2015-02-05 Windward Pharma, Inc. Composés inhibiteurs de tyrosine kinase en aérosol et leurs utilisations
CN106132403B (zh) 2013-10-11 2020-04-28 普尔莫凯恩股份有限公司 喷雾干燥制剂
BR112019008622A2 (pt) 2016-10-27 2019-07-09 Pulmokine Inc método para tratar uma condição
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
WO2020232236A1 (fr) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Formulations d'imatinib, leur fabrication et leurs utilisations
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US20210154193A1 (en) * 2019-11-25 2021-05-27 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
WO2022108939A1 (fr) 2020-11-17 2022-05-27 United Therapeutics Corporation Imatinib inhalé pour le domaine de l'hypertension pulmonaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EP1843771B1 (fr) * 2005-01-28 2011-09-21 Novartis AG Utilisation de pyrimidylaminobenzamides destinees au traitement de maladies qui repondent a la modulation de l'activite tie.2 kinase
EP1879584B1 (fr) * 2005-05-02 2016-06-22 Novartis AG Derives de pyrimidylaminobenzamide contre le syndrome hypereosinophilique
RU2450814C2 (ru) * 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
EA200970447A1 (ru) * 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы

Also Published As

Publication number Publication date
US20110190313A1 (en) 2011-08-04
WO2010019540A1 (fr) 2010-02-18
KR20110053354A (ko) 2011-05-20
IL210922A0 (en) 2011-04-28
RU2011109078A (ru) 2012-09-20
TW201010999A (en) 2010-03-16
BRPI0917491A2 (pt) 2015-12-01
MX2011001668A (es) 2011-03-25
CA2732789A1 (fr) 2010-02-18
NZ590839A (en) 2013-02-22
CL2011000295A1 (es) 2011-07-15
CN102123711A (zh) 2011-07-13
EP2315592A1 (fr) 2011-05-04
JP2011530607A (ja) 2011-12-22
AU2009282104A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
MA32617B1 (fr) Traitement de l'hypertension arterielle pulmonaire
EP2338519A4 (fr) Agent de traitement d'une myélofibrose
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EP2307035A4 (fr) Traitement de l'épilepsie
EP1996612A4 (fr) Compositions destinee au traitement des cancers
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
EP2379084A4 (fr) Modulation de l'expression du facteur 11
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EA201270575A1 (ru) Соединения
EP3957283C0 (fr) Traitement de l'obésité
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
CY2016017I2 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
ATE479673T1 (de) Hemmer der neubildung menschlicher immundefekt- viren
MA33244B1 (fr) Composes de vinylindazolyle
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
EA201170219A1 (ru) Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих
EP2247297A4 (fr) Traitement thérapeutique de conditions pulmonaires
EA201000329A1 (ru) Циклические депсипептиды
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные